1. PREAMBLE: context, listed events, and the conclusion that a waiver is justified—although no actual link is made, such as intellectual property being an obstacle. Lip service on preserving incentives.
7. NO LEGAL CHALLENGE via WTO dispute settlement, including “non-violation” cases—an expected right is lost because of a country’s actions, even when no agreement is violated.
But how is “conformity” established if no legal challenge is allowed?
What’s not in the draft waiver? Terms and conditions
1. CONDITIONS: Other WTO members may want some constraints on applying the waiver—for example to prevent products made under the waiver from being exported to countries that do not use the waiver
A previous waiver contained just such a provision. It required different packaging for easier detection and other methods. India has called this “onerous and time-consuming”
2. TRANSPARENCY: Will actions taken under the waiver have to be notified? This might sound like unnecessary red-tape but it is a fundamental principle of the WTO—legal reference: GATT Art10, GATS Art3, TRIPS Art63.2)
In any case, some notification will be needed—intellectual property agreement Art63.2.
Countries’ laws (except least-developed) comply with the agreement. To use the waiver, they must amend their laws and regulations. That must be notified.
One way to compromise between high protective tariffs and market access
⬇️
Low or zero duty for limited quantities (quotas). Beyond that high tariffs kick in—not “phased in” @nicholaswatt@BBCr4today
1/6
That way the two tariff levels allow some market access but keep it limited so some protection remains for local producers
It’s not the only way to compromise. Another: set a medium-level tariff for all imports of that product. But quantities would depend on supply & demand
2/6
Advantage of a tariff quota: the limit of low/zero duty imports is known. With a medium tariff it is not known.
Disadvantages: complexity in the way the govt hands out the quota among importers, and “quota rent”—benefits, sometimes huge, to those with a share of the quota
Pfizer/BioNTech, Moderna mRNA vaccinations ongoing. J&J approved, not ordered. Supply picking up. Not yet approved: AstraZeneca, Curevac and Novavax. Switzerland has ordered over 30m doses for 8m people